These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34853621)

  • 1. Derivation of a Novel CIHI in Patients with Lung Adenocarcinoma for Estimating Tumor Microenvironment and Clinical Prognosis.
    Zhou L; Xu G; Wang L; Zhang J; Li W
    Dis Markers; 2021; 2021():4495489. PubMed ID: 34853621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
    Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
    Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma.
    Yan Y; Gao Z; Han H; Zhao Y; Zhang Y; Ma X; Chen H
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):565-575. PubMed ID: 34746975
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
    Front Immunol; 2021; 12():677169. PubMed ID: 34354701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma.
    Yuan L; Wu X; Zhang L; Yang M; Wang X; Huang W; Pan H; Wu Y; Huang J; Liang W; Li J; Zhu X; Wang S; Guan J; Liu L
    Cancer Immunol Immunother; 2022 Feb; 71(2):399-415. PubMed ID: 34181042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Immunological Landscape between
    Luo JW; Guo YH; Wu FY; Li XF; Sun XC; Wang JL; Zhou CC
    Dis Markers; 2021; 2021():3776854. PubMed ID: 34484468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
    Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
    Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
    Guo L; Li X; Liu R; Chen Y; Ren C; Du S
    Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.
    Zhang W; Li Y; Lyu J; Shi F; Kong Y; Sheng C; Wang S; Wang Q
    Cancer Sci; 2022 Mar; 113(3):891-903. PubMed ID: 34967077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment.
    Tan Q; Huang Y; Deng K; Lu M; Wang L; Rong Z; Zhao W; Li S; Xu Z; Fan L; Li K; Li Z
    J Cell Biochem; 2020 Nov; 121(11):4569-4579. PubMed ID: 32030808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.
    Yi M; Li A; Zhou L; Chu Q; Luo S; Wu K
    Cancer Immunol Immunother; 2021 Jun; 70(6):1705-1719. PubMed ID: 33386920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 20. Aberrant Expression of β-Catenin Correlates with Infiltrating Immune Cells and Prognosis in NSCLC.
    Zheng H; Ning Y; Yang Y; Zhan Y; Wang H; Wen Q; Peng J; Fan S
    Pathol Oncol Res; 2021; 27():1609981. PubMed ID: 34764821
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.